PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
10907343-7	2000	These results indicate the superiority of both combination therapy of bifonazole + 10% urea ointment (overlapping application group) and occlusive dressing therapy with the same agents in terms of efficacy and safety for the treatment of MTTP, and suggest that they can be recommended for treatment of patients for whom it is difficult to use oral antimycotic agents or for patients who fail to respond to oral medications alone.	bifonazole	70-80	microsomal triglyceride transfer protein	Homo sapiens	238-242
19673350-1	2009	We studied the usefulness of Mycospor Cream 1% (hereinafter referred to as "bifonazole cream"), which was approved 20 years ago in Japan, with once-daily application in 16 patients with tinea pedis (plantar tinea pedis, n = 8; interdigital tinea pedis, n = 8).	bifonazole	76-86	GTF2I repeat domain containing 1	Homo sapiens	38-45
16373351-0	2006	Structure of microsomal cytochrome P450 2B4 complexed with the antifungal drug bifonazole: insight into P450 conformational plasticity and membrane interaction.	bifonazole	79-89	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	35-39
16373351-0	2006	Structure of microsomal cytochrome P450 2B4 complexed with the antifungal drug bifonazole: insight into P450 conformational plasticity and membrane interaction.	bifonazole	79-89	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	104-108
11865326-1	2001	Treatment of cultured rat cerebellar granular cells with calmodulin antagonist bifonazole (10 mM) during oxygen-glucose deprivation or exposure to glutamate (75 mM) prevented neuronal death.	bifonazole	79-89	calmodulin 1	Rattus norvegicus	57-67
10903961-11	2000	These data were confirmed by a direct assay using purified ram seminal vesicle prostaglandin H(2) synthase-1 (PGHS-1), which clearly showed inhibitory properties of econazole (IC(50) 4.7+/-2.3 microM), bifonazole (IC(50) 9.4+/-0.8 microM) and clotrimazole (IC(50) 4.4+/-0.6 microM).	bifonazole	202-212	prostaglandin-endoperoxide synthase 1	Mus musculus	79-108
10903961-11	2000	These data were confirmed by a direct assay using purified ram seminal vesicle prostaglandin H(2) synthase-1 (PGHS-1), which clearly showed inhibitory properties of econazole (IC(50) 4.7+/-2.3 microM), bifonazole (IC(50) 9.4+/-0.8 microM) and clotrimazole (IC(50) 4.4+/-0.6 microM).	bifonazole	202-212	prostaglandin-endoperoxide synthase 1	Mus musculus	110-116
10903961-13	2000	Summarizing, these results indicate an inhibitory effect of econazole, bifonazole and clotrimazole on PGHS-1, varying in its potency dependent on the cell system used.	bifonazole	71-81	prostaglandin-endoperoxide synthase 1	Mus musculus	102-108
16059669-0	2005	Molecular design of two sterol 14alpha-demethylase homology models and their interactions with the azole antifungals ketoconazole and bifonazole.	bifonazole	134-144	cytochrome P450 family 51 subfamily A member 1	Homo sapiens	24-50
2689018-0	1989	A clinical double-blind trial comparing amorolfine cream 0.5% (RO-14-4767) with bifonazole cream 1% in the treatment of dermatomycoses.	bifonazole	80-90	GTF2I repeat domain containing 1	Homo sapiens	91-98
9544799-3	1998	We have previously found that clotrimazole (1-(alpha-2-chlorotrityl)imidazole) and bifonazole (1-(alpha-biphenyl-4-ylbenzyl)imidazole), the antifungal azole derivatives, which were recently recognized as calmodulin antagonists, are calmodulin antagonists which most effectively reduce glycolysis and ATP level in B16 melanoma cells.	bifonazole	83-93	calmodulin 2	Mus musculus	204-214
9544799-3	1998	We have previously found that clotrimazole (1-(alpha-2-chlorotrityl)imidazole) and bifonazole (1-(alpha-biphenyl-4-ylbenzyl)imidazole), the antifungal azole derivatives, which were recently recognized as calmodulin antagonists, are calmodulin antagonists which most effectively reduce glycolysis and ATP level in B16 melanoma cells.	bifonazole	83-93	calmodulin 2	Mus musculus	232-242
8543053-1	1995	The imidazole antimycotics like ketoconazole, clotrimazole, bifonazole, miconazole and CO, known as powerful inhibitors of cytochrome P-450, are potent inhibitors of peroxisomal phytanic acid alpha-oxidation to pristanic acid suggesting the possible involvement of the cytochrome P-450 mono-oxygenase system in this oxidation.	bifonazole	60-70	cytochrome P450 family 20 subfamily A member 1	Homo sapiens	269-300
35298734-5	2022	The minimum fungicidal concentration values for pileus and stipe ranged from 0.06 to 0.60 mg mL- 1, for bifonazole from 0.20 to 0.25 mg mL- 1, and for ketoconazole from 0.30 to 3.50 mg mL- 1.	bifonazole	104-114	L1 cell adhesion molecule	Mus musculus	136-141
9395851-5	1997	Against dermatophytes, MIC for terbinafine (0.05 mg/l) was lower than sertaconazole (MIC 0.41 mg/l) and bifonazole (MIC 1.04 mg/l).	bifonazole	104-114	GTPase-activating protein MDR1	Saccharomyces cerevisiae S288C	116-121
8571391-2	1996	Bifonazole, but not clotrimazole, exhibited the characteristics of a peroxisome proliferator including hepatomegaly (increase in liver:body weight ratio), up to a 4-fold induction of lauric acid omega-hydroxylase activity and an 8-fold induction of palmitoyl-CoA oxidation by rat liver peroxisomes.	bifonazole	0-10	cytochrome P450, family 4, subfamily a, polypeptide 1	Rattus norvegicus	183-212
35526097-2	2022	Following a screen of 1,200 FDA-approved compounds, we identified Bifonazole, an imidazole-based antifungal, as a competitive inhibitor of RBD-ACE2 binding.	bifonazole	66-76	angiotensin converting enzyme 2	Homo sapiens	143-147
35526097-3	2022	Mechanistically, Bifonazole binds ACE2 around residue K353, which consequently prevents association with RBD, thereby impacting entry and replication of Spike-pseudotyped viruses as well as native SARS-CoV-2 and its variants of concern (VOC).	bifonazole	17-27	angiotensin converting enzyme 2	Homo sapiens	34-38
35526097-3	2022	Mechanistically, Bifonazole binds ACE2 around residue K353, which consequently prevents association with RBD, thereby impacting entry and replication of Spike-pseudotyped viruses as well as native SARS-CoV-2 and its variants of concern (VOC).	bifonazole	17-27	surface glycoprotein	Severe acute respiratory syndrome coronavirus 2	153-158
35526097-4	2022	Intranasal administration of Bifonazole reduces lethality in K18-ACE2 mice challenged with VSV-Spike by 40%, with a similar benefit after live SARS-CoV-2 challenge.	bifonazole	29-39	angiotensin I converting enzyme (peptidyl-dipeptidase A) 2	Mus musculus	65-69
35526097-4	2022	Intranasal administration of Bifonazole reduces lethality in K18-ACE2 mice challenged with VSV-Spike by 40%, with a similar benefit after live SARS-CoV-2 challenge.	bifonazole	29-39	surface glycoprotein	Severe acute respiratory syndrome coronavirus 2	95-100
6396116-3	1984	At least in dermatophytes bifonazole additionally inhibits directly HMG-CoA-reductase, the starting and regulatory enzyme in terpenoid biosynthesis, whereas after application of clotrimazole the activity of HMG-CoA-reductase is only decreased by feed-back control, resulting from accumulation of dihydrolanosterol.	bifonazole	26-36	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	68-85
6396116-3	1984	At least in dermatophytes bifonazole additionally inhibits directly HMG-CoA-reductase, the starting and regulatory enzyme in terpenoid biosynthesis, whereas after application of clotrimazole the activity of HMG-CoA-reductase is only decreased by feed-back control, resulting from accumulation of dihydrolanosterol.	bifonazole	26-36	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	207-224
6396116-5	1984	By this, in contrast to clotrimazole, bifonazole possesses a sequential mode of action, namely inhibition of cytochrome P450-dependent C14-demethylation of sterols and direct inhibition of HMG-CoA-reductase.	bifonazole	38-48	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	189-206
6396118-4	1984	Bifonazole cream 1% was shown to be significantly more effective in the treatment of tinea versicolor when used nightly for 2 weeks than was the vehicle cream.	bifonazole	0-10	GTF2I repeat domain containing 1	Homo sapiens	11-18
31839590-7	2020	Of these, dothiepin, cidoxepin, cyclobenzaprine, azatadine, cyproheptadine, bifonazole, and asenapine were indicated to be selective UGT2B10 substrates which have not previously been described.	bifonazole	76-86	UDP glucuronosyltransferase family 2 member B10	Homo sapiens	133-140
33756505-0	2021	Modulation of The Permeability-Inducing Factor Angiopoietin-2 Through Bifonazole in Systemic Inflammation.	bifonazole	70-80	angiopoietin 2	Homo sapiens	47-61
33756505-6	2021	RESULTS: We found that the anti-fungal Bifonazole (BIFO) reduces spontaneous Angpt-2 release in a time- and dose-dependent manner after 8, 12 and 24 h (24 h: veh: 15.6 +- 0.7 vs. BIFO: 8.6 +- 0.8 ng/mL, p < 0.0001).	bifonazole	39-49	angiopoietin 2	Homo sapiens	77-84
33756505-6	2021	RESULTS: We found that the anti-fungal Bifonazole (BIFO) reduces spontaneous Angpt-2 release in a time- and dose-dependent manner after 8, 12 and 24 h (24 h: veh: 15.6 +- 0.7 vs. BIFO: 8.6 +- 0.8 ng/mL, p < 0.0001).	bifonazole	51-55	angiopoietin 2	Homo sapiens	77-84
33756505-8	2021	Stimulation with tumor necrosis factor alpha induced a strong release of Angpt-2 that could analogously be blocked by additional treatment with BIFO (veh: 1.58 +- 0.2 vs. BIFO: 1.02 +- 0.1, p < 0.0001).	bifonazole	144-148	tumor necrosis factor	Homo sapiens	17-44
33756505-8	2021	Stimulation with tumor necrosis factor alpha induced a strong release of Angpt-2 that could analogously be blocked by additional treatment with BIFO (veh: 1.58 +- 0.2 vs. BIFO: 1.02 +- 0.1, p < 0.0001).	bifonazole	144-148	angiopoietin 2	Homo sapiens	73-80
33756505-8	2021	Stimulation with tumor necrosis factor alpha induced a strong release of Angpt-2 that could analogously be blocked by additional treatment with BIFO (veh: 1.58 +- 0.2 vs. BIFO: 1.02 +- 0.1, p < 0.0001).	bifonazole	171-175	tumor necrosis factor	Homo sapiens	17-44
33756505-8	2021	Stimulation with tumor necrosis factor alpha induced a strong release of Angpt-2 that could analogously be blocked by additional treatment with BIFO (veh: 1.58 +- 0.2 vs. BIFO: 1.02 +- 0.1, p < 0.0001).	bifonazole	171-175	angiopoietin 2	Homo sapiens	73-80
33756505-9	2021	Quantification of endothelial permeability by TER revealed that BIFO was sufficient to reduce Thrombin-induced barrier breakdown (veh: 0.82 +- 0.1 vs. BIFO: 1.01 +- 0.02, p < 0.05).	bifonazole	64-68	coagulation factor II, thrombin	Homo sapiens	94-102
33756505-10	2021	CONCLUSION: The antifungal BIFO reduces both release and biosynthesis of the endothelial-destabilizing factor Angpt-2 in vitro thereby improving vascular barrier function.	bifonazole	27-31	angiopoietin 2	Homo sapiens	110-117
31509851-11	2019	Models that were treated with the BFZ-containing ointment after histamine application showed an upregulation of members of the cytochrome P450 family (CAP1A1, CYP1B1, and CYP24A1) and a downregulation of immune response-associated genes (CXCL6, CXCL12, CCL8, IL6, and IL32).	bifonazole	34-37	cytochrome P450 family 1 subfamily B member 1	Homo sapiens	159-165
30579954-1	2019	Hexokinase 1 and 2 have been shown to inhibit Bak- and Bax-mediated apoptosis, leading us to combine the histone deacetylase inhibitor romidepsin with clotrimazole or bifonazole, two compounds that reportedly decrease mitochondrial localization of hexokinases.	bifonazole	167-177	hexokinase 1	Homo sapiens	0-18
30579954-6	2019	We found that a 24 h treatment with clotrimazole or bifonazole decreased total hexokinase 2 expression, resulting in a 76% or 60% decrease, respectively, of mitochondrial expression of hexokinase 2.	bifonazole	52-62	hexokinase 2	Homo sapiens	79-91
30579954-6	2019	We found that a 24 h treatment with clotrimazole or bifonazole decreased total hexokinase 2 expression, resulting in a 76% or 60% decrease, respectively, of mitochondrial expression of hexokinase 2.	bifonazole	52-62	hexokinase 2	Homo sapiens	185-197
30579954-8	2019	Our work suggests that the combination of a short-term romidepsin treatment with bifonazole or clotrimazole leads to increased apoptosis, most likely due to decreased mitochondrial expression of hexokinase 2.	bifonazole	81-91	hexokinase 2	Homo sapiens	195-207
31509851-11	2019	Models that were treated with the BFZ-containing ointment after histamine application showed an upregulation of members of the cytochrome P450 family (CAP1A1, CYP1B1, and CYP24A1) and a downregulation of immune response-associated genes (CXCL6, CXCL12, CCL8, IL6, and IL32).	bifonazole	34-37	cytochrome P450 family 24 subfamily A member 1	Homo sapiens	171-178
31509851-11	2019	Models that were treated with the BFZ-containing ointment after histamine application showed an upregulation of members of the cytochrome P450 family (CAP1A1, CYP1B1, and CYP24A1) and a downregulation of immune response-associated genes (CXCL6, CXCL12, CCL8, IL6, and IL32).	bifonazole	34-37	C-X-C motif chemokine ligand 6	Homo sapiens	238-243
31509851-11	2019	Models that were treated with the BFZ-containing ointment after histamine application showed an upregulation of members of the cytochrome P450 family (CAP1A1, CYP1B1, and CYP24A1) and a downregulation of immune response-associated genes (CXCL6, CXCL12, CCL8, IL6, and IL32).	bifonazole	34-37	C-X-C motif chemokine ligand 12	Homo sapiens	245-251
31509851-11	2019	Models that were treated with the BFZ-containing ointment after histamine application showed an upregulation of members of the cytochrome P450 family (CAP1A1, CYP1B1, and CYP24A1) and a downregulation of immune response-associated genes (CXCL6, CXCL12, CCL8, IL6, and IL32).	bifonazole	34-37	C-C motif chemokine ligand 8	Homo sapiens	253-257
31509851-11	2019	Models that were treated with the BFZ-containing ointment after histamine application showed an upregulation of members of the cytochrome P450 family (CAP1A1, CYP1B1, and CYP24A1) and a downregulation of immune response-associated genes (CXCL6, CXCL12, CCL8, IL6, and IL32).	bifonazole	34-37	interleukin 6	Homo sapiens	259-262
31509851-11	2019	Models that were treated with the BFZ-containing ointment after histamine application showed an upregulation of members of the cytochrome P450 family (CAP1A1, CYP1B1, and CYP24A1) and a downregulation of immune response-associated genes (CXCL6, CXCL12, CCL8, IL6, and IL32).	bifonazole	34-37	interleukin 32	Homo sapiens	268-272
24849495-0	2014	The mechanism of bifonazole-induced [Ca(2+)]i rises and non-Ca(2+)-triggered cell death in PC3 human prostate cancer cells.	bifonazole	17-27	chromobox 8	Homo sapiens	91-94
25569586-0	2015	Crystallization of bifonazole and acetaminophen within the matrix of semicrystalline, PEO-PPO-PEO triblock copolymers.	bifonazole	19-29	protoporphyrinogen oxidase	Homo sapiens	90-93
25569586-5	2015	Observed under polarized optical microscopy, PEG, PPG, and poloxamer could all significantly improve the crystallization rate of ACM and BFZ, because of the largely reduced Tg of the solid dispersions by these low Tg polymers.	bifonazole	137-140	serglycin	Homo sapiens	50-53
24849495-3	2014	The effect of bifonazole on cytosolic free Ca(2+) concentrations ([Ca(2+)]i) and viability in PC3 human prostate cancer cells was explored.	bifonazole	14-24	chromobox 8	Homo sapiens	94-97
24849495-12	2014	Annexin V/propidium iodide staining data suggest that bifonazole (30-100 microM) induced apoptosis concentration-dependently.	bifonazole	54-64	annexin A5	Homo sapiens	0-9
24849495-13	2014	Together, in PC3 human prostate cancer cells, bifonazole induced [Ca(2+)]i rises by inducing phospholipase C- and protein kinase C-dependent Ca(2+) release from the endoplasmic reticulum and Ca(2+) influx via non-store-operated pathways.	bifonazole	46-56	chromobox 8	Homo sapiens	13-16